Necitumumab in NSCLC: Indication of minor added benefit for patients with metastases

July 04, 2016

The monoclonal antibody necitumumab has been approved since February 2016 for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for this condition. The drug is used in combination with gemcitabine and cisplatin.

In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) now examined the advantages and disadvantages of this combination. According to the findings, there is an indication of a minor added benefit of necitumumab in combination with gemcitabine and cisplatin in comparison with the appropriate comparator therapy cisplatin in combination with a third-generation cytostatic agent for patients with metastases. It is unclear whether the observed effects are transferable to patients without metastases.

Study only in patients with metastases

The benefit assessment was based on the study SQUIRE. Patients whose NSCLC did not express the EGFR also participated in this study, however. Their data were excluded from the analysis to comply with the Summary of Product Characteristics of necitumumab. All patients had stage IV of the disease, i.e. had metastases. Based on this study, no conclusions can be drawn on an added benefit for patients with locally advanced NSCLC (stage IIIB).

Survival advantage, but also disadvantages

There was an indication of considerable added benefit of the combination therapy with necitumumab in comparison with the comparator therapy in the outcome "overall survival". In the morbidity outcome "symptoms", the effect was influenced by ethnicity; there was no hint of an added benefit for the main ethnicity in the health care area (Caucasians). In the outcome category "side effects", the new treatment was associated with disadvantages of different extent, some of which only applied to subgroups.

Transferability to patients without metastases unclear

In the overall consideration, these negative effects did not outweigh the advantage in overall survival, but led to a downgrading of the extent. Hence an indication of a minor added benefit of necitumumab in combination with gemcitabine and cisplatin in comparison with the appropriate comparator therapy remains for patients with metastatic NSCLC. It remains unclear in how far these conclusions are transferable to patients with locally advanced, not yet metastatic NSCLC.

G-BA decides on the extent of added benefit

The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the Federal Joint Committee (G-BA). After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.
-end-
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the Website gesundheitsinformation.de, published by IQWiG, provides easily understandable German-language information.

More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on informedhealth.org). If you would like to be informed when these documents are available, please send an e-mail to » info@iqwig.de.

Institute for Quality and Efficiency in Health Care

Related Health Care Articles from Brightsurf:

Study evaluates new World Health Organization Labor Care Guide for maternity care providers
The World Health Organization developed the new Labor Care Guide to support clinicians in providing good quality, women-centered care during labor and childbirth.

Six ways primary care "medical homes" are lowering health care spending
New analysis of 394 U.S. primary care practices identifies the aspects of care delivery that are associated with lower health care spending and lower utilization of emergency care and hospital admissions.

Modifiable health risks linked to more than $730 billion in US health care costs
Modifiable health risks, such as obesity, high blood pressure, and smoking, were linked to over $730 billion in health care spending in the US in 2016, according to a study published in The Lancet Public Health.

Spending on primary care vs. other US health care expenditures
National health care survey data were used to assess the amount of money spent on primary care relative to other areas of health care spending in the US from 2002 to 2016.

MU Health Care neurologist publishes guidance related to COVID-19 and stroke care
A University of Missouri Health Care neurologist has published more than 40 new recommendations for evaluating and treating stroke patients based on international research examining the link between stroke and novel coronavirus (COVID-19).

Large federal program aimed at providing better health care underfunds primary care
Despite a mandate to help patients make better-informed health care decisions, a ten-year research program established under the Affordable Care Act has funded a relatively small number of studies that examine primary care, the setting where the majority of patients in the US receive treatment.

International medical graduates care for Medicare patients with greater health care needs
A study by a Massachusetts General Hospital research team indicates that internal medicine physicians who are graduates of medical schools outside the US care for Medicare patients with more complex medical needs than those cared for by graduates of American medical schools.

The Lancet Global Health: Improved access to care not sufficient to improve health, as epidemic of poor quality care revealed
Of the 8.6 million deaths from conditions treatable by health care, poor-quality care is responsible for an estimated 5 million deaths per year -- more than deaths due to insufficient access to care (3.6 million) .

Under Affordable Care Act, Americans have had more preventive care for heart health
By reducing out-of-pocket costs for preventive treatment, the Affordable Care Act appears to have encouraged more people to have health screenings related to their cardiovascular health.

High-deductible health care plans curb both cost and usage, including preventive care
A team of researchers based at IUPUI has conducted the first systematic review of studies examining the relationship between high-deductible health care plans and the use of health care services.

Read More: Health Care News and Health Care Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.